10x Genomics, Inc. — Director's Dealing 2021

Apr 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-04-01

Reporting Person: McAnear Justin J. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-01	Class A Common Stock	M	10000	$5.04	Acquired	40357	Direct
2021-04-01	Class A Common Stock	S	300	$180.0233	Disposed	40057	Direct
2021-04-01	Class A Common Stock	S	200	$181.825	Disposed	39857	Direct
2021-04-01	Class A Common Stock	S	700	$183.1871	Disposed	39157	Direct
2021-04-01	Class A Common Stock	S	3205	$184.1172	Disposed	35952	Direct
2021-04-01	Class A Common Stock	S	3795	$185.0203	Disposed	32157	Direct
2021-04-01	Class A Common Stock	S	1800	$185.7561	Disposed	30357	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-01	Stock Option (right to buy)	$5.04	M	10000	Disposed	2028-11-02	Class A Common Stock (10000)	Direct

Footnotes

F1: This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $179.97 to $180.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $181.56 to $182.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $182.61 to $183.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $183.62 to $184.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $184.62 to $185.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: This transaction was executed in multiple trades at prices ranging from $185.62 to $186.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F8: This option, originally for 600,000 shares, of which 159,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.